Journey Medical Corporation has begun the first of two phase 3 trials evaluating DFD-29 for the treatment of papulopustular rosacea, the company announced in a press release.
The first of up to 340 patients has received DFD-29 — minocycline modified release capsules 40 mg — in a multicenter, randomized, double-blind, parallel-group trial. There will be both an active and placebo-controlled trial.
In the studies, participants will be randomly assigned 3:3:2 to receive DFD-29, doxycycline capsules 40 mg (Oracea, USP) or placebo for 16 weeks.
“Reaching this milestone marks another